BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Dow
Cantor Fitzgerald
Fish and Richardson
Cerilliant
Moodys
Novartis
Queensland Health
Medtronic

Generated: January 19, 2018

DrugPatentWatch Database Preview

Aprepitant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for aprepitant and what is the scope of aprepitant freedom to operate?

Aprepitant
is the generic ingredient in two branded drugs marketed by Glenmark Pharms Ltd, Sandoz, Merck, and Msd Merck Co, and is included in four NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Aprepitant has eighty-eight patent family members in forty-four countries.

There are twenty-three drug master file entries for aprepitant. Five suppliers are listed for this compound.

US Patents and Regulatory Information for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-001 Sep 24, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glenmark Pharms Ltd APREPITANT aprepitant CAPSULE;ORAL 207777-002 Oct 12, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-003 Sep 24, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-002 Sep 24, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for aprepitant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,229,010 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
6,432,953 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for aprepitant

Supplementary Protection Certificates for aprepitant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004 Austria ➤ Subscribe PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
C/GB04/011 United Kingdom ➤ Subscribe PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
C/GB08/021 United Kingdom ➤ Subscribe PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0019 France ➤ Subscribe PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
2004002 Lithuania ➤ Subscribe PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
2004002,C0734381 Lithuania ➤ Subscribe PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C0010 France ➤ Subscribe PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cantor Fitzgerald
Harvard Business School
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Express Scripts
McKesson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot